Example: Heart Attack

Clinical Trials on Anemia, Refractory, with Excess of Blasts

Total 199 results

NCT04599426

Not yet recruiting

Allogenic NK Cell Transfusion Azacitidine MDS-EB

Conditions: MDS-EB
NCT04027309

Recruiting

A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy

Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndrome With Excess Blasts-2
NCT03338348

Completed

Study of Vosaroxin With Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2

Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndrome With Excess Blasts-2 (MDS-EB-2)
NCT03217903

Recruiting

High Risk Myelodysplasia Treated by Azacytidine : Genetic and Epigenetic (MYRAGE)

Conditions: High-risk Myelodysplastic Syndromes With Excess Blasts
NCT03839771

Recruiting

A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy

Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndrome With Excess Blasts-2
NCT04216355

Recruiting

Low-dose AZA Combined With Short Term CAG Derived Regimen as a Bridging Treatment in Patients With Advanced MDS Prior to Allo-HSCT

Conditions: MDS-EB
NCT03175978

Active, not recruiting

IGF-MTX Conjugate in the Treatment of Myelodysplastic Syndrome

Conditions: Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Anemia, Refractory, With Excess of Blasts
NCT01928537

Completed

Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine

Conditions: Myelodysplastic Syndromes; Refractory Anemia With Excess Blasts; Chronic Myelomonocytic Leukemia; Cytopenia
NCT04526288

Not yet recruiting

CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease

Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndrome With Excess Blasts-2; Myeloid Neoplasm
NCT04628026

Not yet recruiting

Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2

Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndromes
NCT01461538

Completed

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Conditions: Acute Lymphoid Leukemia; Acute Myeloid Leukemia; Anemia, Refractory, With Excess of Blasts; Solid Tumors
NCT04636918

Recruiting

Ikervis for DED Due to GVHD Post Allo-HSCT

Conditions: Leukemia (Both ALL and AML); MDS-EB-1
NCT00038051

Completed

Evaluation of the Anti-CD-33 Immunotoxin Hum-195/rGel in Patients With Advanced Myeloid Malignancies

Conditions: Acute Myeloid Leukemia; Chronic Myelomonocytic Leukemia; Myeloproliferative Disorders; Anemia, Refractory, With Excess of Blasts
NCT00278330

Completed

Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory Anemia

Conditions: Blastic Phase Chronic Myelogenous Leukemia; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Refractory Anemia With Excess Blasts; Relapsing Chronic Myelogenous Leukemia; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Adult Acute Myeloid Leukemia
NCT01463410

Terminated

Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler

Conditions: Acute Myeloid Leukemia (AML); Acute Promyelocytic Leukemia (APL); Refractory Anemia With Excess of Blasts (RAEB)
NCT00209833

Unknown status

Treatment of Adults Aged Up to 60 Years With De Novo Acute Myeloblastic Leukaemia,Secondary AML, or RAEB-T

Conditions: De Novo Akute Myeloid Leukemia (AML); Secondary Acute Myeloid Leukemia (AML); Refractory Anemia With Excess of Blasts in Transformation
NCT03092674

Active, not recruiting

Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndrome; Myelodysplastic Syndrome With Excess Blasts-2
NCT00121303

Completed

Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes

Conditions: Leukemia; Myelodysplastic Syndromes
NCT00809250

Completed

Vaccination With GM-K562 Cells in Patients With Advanced Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) After Allogeneic Hematopoetic Stem Cell Transplantation

Conditions: Acute Myeloid Leukemia; Chronic Myelomonocytic Leukemia; Myelodysplastic Syndrome-Refractory Anemia With Excess Blasts
NCT00046930

Completed

Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia

Conditions: Leukemia; Myelodysplastic Syndromes
NCT02562443

Active, not recruiting

Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA

Conditions: Myelodysplastic Syndrome; MDS; Refractory Anemia With Excess Blasts; RAEB
NCT00005942

Completed

Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial Therapy

Conditions: Chronic Myelomonocytic Leukemia; Previously Treated Myelodysplastic Syndromes; Recurrent Adult Acute Myeloid Leukemia; Refractory Anemia With Excess Blasts; Refractory Anemia With Excess Blasts in Transformation
NCT00363025

Terminated

A Randomized Study of Post-Remission Therapy in Elderly Patients With Acute Myelogenous Leukemia.

Conditions: Acute Myeloid Leukemia
NCT01834248

Completed

DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Conditions: Acute Myeloid Leukemia; Alkylating Agent-Related Acute Myeloid Leukemia; Chronic Myelomonocytic Leukemia; Myelodysplastic Syndrome; Refractory Anemia With Excess Blasts in Transformation
NCT02553941

Active, not recruiting

Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome

Conditions: Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome; Refractory Anemia With Excess Blasts in Transformation; Secondary Myelodysplastic Syndrome